ANI Pharmaceuticals, Inc.

NASDAQ:ANIP

Drug Manufacturers - Specialty & Generic

Healthcare
$71.47 -1.76%

-$1.42 today

Market cap
$1.62B
Beta
0.44
P/E (TTM)
18.5
EPS (TTM)
$4.29
52W Low $62.61High $99.50

Volume 0.29M

Average 0.35M

ANIP EBITDA Margin

EBITDA as a percentage of revenue.

ANI Pharmaceuticals, Inc.NASDAQ: ANIP

EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026

EBITDA Margin holds steady near 24.2%

EBITDA Margin was 24.2% in Q1 FY2026, down 0.4 pp from a year earlier. On a trailing-twelve-month basis it was 25.4%, up 15.5 pp year over year. Over 3 fiscal years it widened by 15.5 pp.

Context

  • EBITDA Margin widened in 2 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 6 analysts of 31.9% for the fiscal year ending Dec 2026, up from 23.5% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
24.2%-7.0 pp QoQ
Last fiscal yearDec 2025
23.5%+13.2 pp YoY
LTMMar 2026
25.4%+15.5 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-0.4 pp+11.0 pp+11.4 pp
1 year+13.2 pp+8.5 pp-4.7 pp
3 years+15.5 pp+6.7 pp-8.9 pp
5 years+5.5 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
23.5%
Year-over-year change
+13.2pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How ANIP compares with its peers on the latest reported figures

  • ANIP's LTM Mar 2026 EBITDA Margin of 25.4% is the 3rd highest of the 11 companies compared; the peer median is 17.4%.
  • Its year-over-year change of +15.5 pp is the 3rd highest of 10, against a peer median of +0.5 pp.
  • Over three fiscal years its change of +15.5 pp compares with a peer median of +0.2 pp.
ANIP Competitors Peer median
EBITDA Margin for ANIP and competitors
Company Period LTM level YoY 3-year change
COLLCollegium Pharmaceutical, Inc.LTM Mar 202676.6% +26.5 pp+14.0 pp
AMPHAmphastar Pharmaceuticals, Inc.LTM Mar 202626.6% -9.0 pp+0.2 pp
ANIPANI Pharmaceuticals, Inc.LTM Mar 202625.4% +15.5 pp+15.5 pp
AMRXAmneal Pharmaceuticals, Inc.LTM Jun 202620.9% +0.5 pp+0.1 pp
BHCBausch Health Companies Inc.LTM Jun 202618.9% -14.3 pp-4.5 pp
VTRSViatris Inc.LTM Jun 202618.4% +21.9 pp-42.3 pp
RDYDr. Reddy's Laboratories LimitedLTM Sep 202616.3% -12.5 pp-6.7 pp
TEVATeva Pharmaceutical Industries LimitedLTM Jun 202615.0% -2.9 pp+24.4 pp
HROWHarrow Health, Inc.LTM Mar 202611.7% +3.4 pp+19.6 pp
LFCRLifecore Biomedical, Inc.LTM Mar 2026-0.8% —-18.4 pp
EOLSEvolus, Inc.LTM Mar 2026-4.6% +6.2 pp+28.7 pp
Peer median (excluding ANIP) 17.4%+0.5 pp+0.2 pp

Competitors are the stored peer set for ANIP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue216.14M316.39M486.82M614.38M883.37M
Cost of Revenue100.61M138.79M181.51M250.21M432.73M
Gross Profit115.53M177.6M305.3M364.17M450.64M
Gross Margin53.5%56.1%62.7%59.3%51.0%
Research & Development11.37M22.32M34.29M44.58M51.66M
Selling, General & Admin84.29M124.04M161.7M249.64M317.75M
Operating Expenses155.32M212.88M258.33M363.58M369.41M
Depreciation & Amortization47.25M59.65M59.79M67.73M91.42M
EBITDA3.12M25.04M106.6M63.12M207.27M
EBITDA Margin1.4%7.9%21.9%10.3%23.5%
Operating Income(39.79M)(35.28M)46.97M584K81.23M
Operating Margin-18.4%-11.2%9.6%0.1%9.2%
Interest Income00000
Interest Expense11.92M28.05M26.94M17.6M20.06M
Other Income / Expenses(16.27M)(27.38M)(27.1M)(22.8M)14.56M
Income Before Tax(56.06M)(62.67M)19.87M(22.21M)95.79M
Pre-Tax Margin-25.9%-19.8%4.1%-3.6%10.8%
Income Tax Expense(13.46M)(14.77M)1.09M(3.69M)17.45M
Net Income(42.6M)(47.9M)18.78M(18.52M)78.34M
Net Margin-19.7%-15.1%3.9%-3.0%8.9%
EPS (Basic)(3.40)(3.05)0.95(1.04)3.50
EPS (Diluted)(3.40)(3.05)0.94(1.04)3.32
Weighted Avg Shares12.6M16.26M18M19.32M20.05M
Weighted Avg Shares (Diluted)12.6M16.26M18.19M19.32M21.23M

ANI Pharmaceuticals, Inc.

NASDAQ:ANIP

Intrinsic Alpha fair value

Locked

Current Price

$71.47

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.